New #Stocks to Watch at Investor Ideas – Biotech (NASDAQ: $EVGN), Cannabis (CSE: $JUVA.C), Plant-Based Foods (CSE: $EATS.C) and CyberSecurity (NASDAQ: $TLS)

 

New #Stocks to Watch at Investor Ideas – Biotech (NASDAQ: $EVGN), Cannabis (CSE: $JUVA.C), Plant-Based Foods (CSE: $EATS.C) and CyberSecurity (NASDAQ: $TLS)

 

Point Roberts WA, Delta BC, December 4, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis, Plant-Based Foods, CyberSecurity, Mining and China-Asia. Today’s stocks in have been added to our list of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2020/main/12041Stocks.asp

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

The newest biotech companies are all life sciences companies and include recent Nasdaq IPOs.

 

The latest cannabis companies are both CSE listed, with Pure Extracts Technologies Corp. (CSE:PULL) crossing into functional mushrooms/psychedelics.

 

Also CSE-listed are the newest plant-based/vegan companies, along with the latest mining company.

 

The newest cybersecurity and China companies are both Nasdaq IPOS from November.

 

New Stocks added to Biotech stocks directory:

Evogene Ltd. (NasdaqGM:EVGN) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production

 

Sotera Health Co (NasdaqGS:SHC) is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

 

MARAVAI LIFESCIENCES HOLDINGS, INC. (NasdaqGS:MRVI) is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

 

New Stocks added to Cannabis stocks directory:

Juva Life Inc. (CSE:JUVA) is a vertically-integrated cannabis company with deep roots in California cannabis culture and extensive expertise in all areas of cannabis production and sales, from cultivation through research and manufacturing to walk-in and delivery retail.

 

Pure Extracts Technologies Corp. (CSE:PULL) is an integrated Canadian plant-based extraction company specializing in the processing of cannabis, hemp and functional mushrooms to produce oils and various derivative products. The company is involved in white labeling activities as well as selling branded oil based products under the Pure Extracts brand. The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act

 

New Stocks added to Plant-based/Vegan stocks directory:

Eat Beyond Global Holdings Inc. (CSE:EATS) is an investment issuer that identifies and makes equity investments in global plant based protein companies that are developing and commercializing innovative food tech as well as alternative food products. The company provides retail investors with the unique opportunity to participate in the growth of a broad cross-section of opportunities in the alternative food sector, and access companies that are leading the charge toward a smarter, more secure food supply.

 

Plant & Co. Brands Ltd. (CSE:VEGN) formerly Euorlife Brands is a vertically integrated enterprise focused on the health and wellness sector. With a network of high-level contacts in the food and beverage industries across North America, South America and Europe, the executive team at EuroLife Brands is working toward a number of strategic partnerships to strengthen EuroLife’s offering of innovative plant-based food alternatives. Working diligently with their colleagues in the health and wellness industry, EuroLife plans to execute several joint ventures to bring together players from across various sectors to offer their strengths in creating a new and exciting lineup of plant-based foods for health-conscious consumers to enjoy. With deals already in place for plant-based beverages such as coffee and tea, EuroLife plans to move aggressively to expand its portfolio through mutually-beneficial partnerships, mergers, acquisitions, joint ventures and more.

 

New Stocks added to CyberSecurity stocks directory:

TELOS CORP (NasdaqGS:TLS) empowers and protects the world’s most security-conscious organizations with solutions for continuous security assurance of individuals, systems, and information. Telos’ offerings include cybersecurity solutions for IT risk management and information security; cloud security solutions to protect cloud-based assets and enable continuous compliance with industry and government security standards; and enterprise security solutions to ensure that personnel can work and collaborate securely and productively. The company serves military, intelligence and civilian agencies of the federal government, allied nations and commercial organizations around the world.

 

New Stocks added to Mining stocks directory:

Mosaic Minerals Corp. (CSE:MOC) (“Mosaic”) is a Canadian company whose principal business activity is the exploration, acquisition and development of mineral properties in Canada. Mosaic is currently focusing on the exploration and development of its recently acquired mineral property, the Opawica Project located south of Chibougamau in the province of Quebec, which is 100% owned by the company

 

New Stocks added to China-Asia stocks directory:

Yatsen Holding Ltd (NYSE:YSG) is a leader in the rapidly evolving China beauty market with the mission of creating an exciting new journey of beauty discovery for consumers in China and around the world. The Company has launched three fast-growing, successful color cosmetics and skincare brands: Perfect Diary, Little Ondine and Abby's Choice, and has recently acquired Galénic, an iconic premium skincare brand. Leveraging its digitally native direct-to-customer business model, the Company has built a platform with core capabilities that disrupt every part of the traditional beauty industry value chain and deliver greater value to its customers. The Company reaches and engages with customers directly both online and offline, with expansive presence across all major e-commerce, social and content platforms in China.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 

 

 

 

 

 

 

 

 

 

#MedTech #Stocks in the News: Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines From Human Blood Plasma; @Sigyn_inc

 

#MedTech #Stocks in the News: Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines From Human Blood Plasma; @Sigyn_inc

 

SAN DIEGO, CA, December 2, 2020 / -(Investorideas.com newswire) Breaking Medical Tech/ therapeutic technology stock news -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on treating life-threatening inflammatory conditions, today announced the completion of an in vitro study that demonstrated the ability of Sigyn Therapy™ to clear both endotoxin and inflammatory cytokines from human blood plasma. 

 

Read this news featuring SIGY in full at https://www.investorideas.com/news/2020/biotech/12021Sigyn-Therapeutics-Endotoxin-Cytokines.asp

 

Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome, which precipitates a wide-range of life-threatening conditions, including sepsis, the most common cause of hospital deaths.  Virus induced cytokine storm syndrome is associated with high mortality and currently is a leading cause of SARS-CoV-2 (COVID-19) deaths.  Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines located in hospitals and clinics worldwide.

 

In the in vitro study, Sigyn Therapy simultaneously reduced the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

 

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.  The resulting data will be incorporated into an Investigational Device Exemption (IDE) that Sigyn plans to submit to the United States Food and Drug Administration (FDA) in 2021.

 

“The simultaneous clearance of endotoxin and inflammatory cytokines is a significant milestone that reinforces the potential of Sigyn Therapy to overcome the limitations of industry pioneering devices that are currently deployed to treat life-threatening inflammatory conditions,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics.

 

At present, the CytoSorb device from CytoSorbents Corporation and the Toraymyxin device from Toray Industries are market cleared and broadly administered to treat a wide-range of life-threatening inflammatory conditions outside of the United States. In regards to mechanism, the Toraymyxin device has a high specificity to bind circulating endotoxin, but does not address inflammatory cytokines. Conversely, the CytoSorb device depletes inflammatory cytokines from circulation, but does not address endotoxin.

 

In addition to reporting the dual clearance of endotoxin and inflammatory cytokines, the Company further disclosed that it plans to evaluate the ability of Sigyn Therapy to address other inflammatory targets, including CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream.  The Company believes that Sigyn Therapy is the first therapeutic candidate to target circulating CytoVesicles.

 

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

 

Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring (OTCMARKETS: SIGY) is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com

 

 

 

 

 

 

#MedicalTech/ #TherapeuticTechnology #Stock News -Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines from Human Blood Plasma; @Sigyn_inc

 

#MedicalTech/ #TherapeuticTechnology #Stock News -Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines from Human Blood Plasma; @Sigyn_inc

 

Sigyn Therapy™ is a Candidate to Treat Sepsis and Other Life-Threatening Inflammatory Conditions That Are Not Addressed with Approved Drugs

 

SAN DIEGO, CA, December 1, 2020 / -(Investorideas.com newswire) Breaking Medical Tech/ therapeutic technology stock news -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on treating life-threatening inflammatory conditions, today announced the completion of an in vitro study that demonstrated the ability of Sigyn Therapy™ to clear both endotoxin and inflammatory cytokines from human blood plasma. 

 

Read this news featuring SIGY in full at https://www.investorideas.com/news/2020/biotech/12011SIGY-Endotoxin-Cytokines.asp

 

Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome, which precipitates a wide-range of life-threatening conditions, including sepsis, the most common cause of hospital deaths.  Virus induced cytokine storm syndrome is associated with high mortality and currently is a leading cause of SARS-CoV-2 (COVID-19) deaths.  Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines located in hospitals and clinics worldwide.

 

In the in vitro study, Sigyn Therapy simultaneously reduced the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

 

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.  The resulting data will be incorporated into an Investigational Device Exemption (IDE) that Sigyn plans to submit to the United States Food and Drug Administration (FDA) in 2021.

 

“The simultaneous clearance of endotoxin and inflammatory cytokines is a significant milestone that reinforces the potential of Sigyn Therapy to overcome the limitations of industry pioneering devices that are currently deployed to treat life-threatening inflammatory conditions,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics.

 

At present, the CytoSorb device from CytoSorbents Corporation and the Toraymyxin device from Toray Industries are market cleared and broadly administered to treat a wide-range of life-threatening inflammatory conditions outside of the United States. In regards to mechanism, the Toraymyxin device has a high specificity to bind circulating endotoxin, but does not address inflammatory cytokines. Conversely, the CytoSorb device depletes inflammatory cytokines from circulation, but does not address endotoxin.

 

In addition to reporting the dual clearance of endotoxin and inflammatory cytokines, the Company further disclosed that it plans to evaluate the ability of Sigyn Therapy to address other inflammatory targets, including CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream.  The Company believes that Sigyn Therapy is the first therapeutic candidate to target circulating CytoVesicles.

 

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

 

Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring (OTCMARKETS: SIGY) is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com